TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16687201
Drug: Double IUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double IUI performed 12 and 36 h after HCG administration
Study: 15635799
Drug: IFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha 2 b (5MU sqm/daily)
Study: 15635799
Drug: IFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha 2 b (5MU sqm/daily) plus monthly courses of low-dose AraC
Study: 6206105
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with a mean cumulative dose of cat allergen, 10.9 units
Study: 29101777
Drug: Real PENS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real PENS therapy with etoricoxib, 3 times per week for 8 weeks
Study: 29101777
Drug: Sham PENS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham PENS therapy with etoricoxib, 3 times per week for 8 weeks
Study: 19524262
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Parecoxib
Study: 19524262
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline solution
Study: 18030450
Drug: Ayahuasca (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (1 mg DMT kg(‐1) body weight)
Study: 8024729
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy for 15 months
Study: 2509380
Drug: TDN 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDN 20 (transdermal nitroglycerin patches, 20 mg over 24 h)
Study: 2509380
Drug: Chronic TDN
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic TDN treatment
Study: 911371
Drug: Chemotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group (clofibrate 1 g twice daily and nicotinic acid 1 g three times daily)
Study: 28197931
Drug: LSD 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD 200 µg
Study: 29055031
Drug: Gender-neutral vaccination
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (Arm A)
Study: 18852481
Drug: Sequential Combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Combined Treatment (SCT)
Study: 18852481
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TU)
Study: 15730352
Drug: Cabergoline 0.5
Normalized name: cabergoline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5 mg per week
Study: 18788838
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily
Study: 15730352
Drug: Hydergine 1
Normalized name: Hydergine 1mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine 1 mg three times daily
Study: 15730352
Drug: Levodopa/carbidopa 25/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 25/100 mg three times daily
Study: 10979909
Drug: II CPS-TT
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: II CPS-TT conjugate vaccine (dose range, 3.6-57 microg of CPS component)
Study: 10979909
Drug: Uncoupled II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoupled II CPS vaccine
Study: 8684103
Drug: Serum 1,5-anhydroglucitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 1,5-anhydroglucitol (1,5AG) monitoring in group A (continuous treatment)
Study: 8684103
Drug: Serum 1,5-anhydroglucitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 1,5-anhydroglucitol (1,5AG) monitoring in group B (intermittent treatment)
Study: 8684103
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of 1,5AG with FPG and mean daily plasma glucose
Study: 1611648
Drug: Loracarbef 400
Normalized name: loracarbef 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef 400 mg twice daily for 10 to 14 days
Study: 1611648
Drug: Amoxicillin/clavulanate 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 500/125 mg three times daily for 10 to 14 days
Study: 6705901
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose antidepressants (75 mg/day)
Study: 6705901
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antidepressants (150 mg/day)
Study: 22571507
Drug: No antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifungal treatment (Arm A)
Study: 11837553
Drug: Everolimus 2
Normalized name: everolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2 mg orally under fasting conditions
Study: 11837553
Drug: Everolimus 2
Normalized name: everolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2 mg orally after a high-fat meal
Study: 11837553
Drug: Everolimus 2.5
Normalized name: everolimus 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2.5 mg/day orally in patients with renal transplants under fasting conditions
Study: 11837553
Drug: Everolimus 2.5
Normalized name: everolimus 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 2.5 mg/day orally in patients with renal transplants after a high-fat meal
Study: 8672324
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (serum concentrations > or = 200 kiu ml‐1)
Study: 29321047
Drug: MAG‐EPA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG‐EPA supplementation (6 capsules of 625 mg of fish oil daily, containing 500 mg of EPA)
Study: 26526300
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TNA) applied during and after intense pulsed light (IPL) treatment.
Study: 26526300
Drug: Vehicle (control)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control) applied during and after intense pulsed light (IPL) treatment.
Study: 16369731
Drug: bLF tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: bLF tablets at a dosage of 200 mg b.i.d. for a period of 12 weeks
Study: 16369731
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets without bLF
Study: 9644751
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg daily for 3 days
Study: 9396979
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 60 mg bid
Study: 9396979
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 120 mg bid
Study: 9396979
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 240 mg bid
Study: 31718402
Drug: Geisinger Maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Geisinger Maternal Fetal Medicine obesity protocol (MOP)
Study: 30876777
Drug: Intradermal mesotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal mesotherapy with tenoxicam
Study: 30876777
Drug: Intravenous dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexketoprofen (control)
Study: 22140199
Drug: Computer-based compensatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based compensatory therapy (CT)
Study: 3606369
Drug: Standard occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard occupational therapy (OT)
Study: 17272964
Drug: Donepezil (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5-10 mg)
Study: 7892894
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (60 to 80 mg daily from 12 weeks' gestation until delivery)
Study: 9624239
Drug: no chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no chemotherapy
Study: 1111463
Drug: continued melphalan-prednisone
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continued melphalan-prednisone chemotherapy
Study: 28084175
Drug: Antidiabetic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic drugs (including metformin)
Study: 28084175
Drug: Thiazolidinediones or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinediones or insulin
Study: 28084175
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of antidiabetic drugs
Study: 22164968
Drug: Coated azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Coated azithromycin powder for suspension (Tridosil 200 mg/5 ml)
Study: 22164968
Drug: Uncoated azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Uncoated azithromycin powder for suspension (200 mg/5 ml)
Study: 19896041
Drug: Platelet-enriched gel
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-enriched gel
Study: 19896041
Drug: Non-gel group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-gel group
Study: 21067346
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg once daily)
Study: 9221708
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg once daily)
Study: 10394450
Drug: Intraoral saccharose
Normalized name: Saccharose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral saccharose administration
Study: 8707972
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg q.i.d. plus scaling
Study: 8707972
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg q.i.d. alone
Study: 1649971
Drug: Foscarnet (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (40 mg/kg IV every 8 hours)
Study: 1649971
Drug: Vidarabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine (15 mg/kg IV per day)
Study: 6341914
Drug: 1% solution
Normalized name: GUMSOL 5%-0.01% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% solution of fenoprofen sodium
Study: 30236110
Drug: Inhaled saline
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled saline (4 ml)
Study: 29231358
Drug: Clomiphene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (50 mg per day for 5 consecutive days)
Study: 24640990
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 1000 mg rituximab
Study: 24640990
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 500 mg rituximab
Study: 22946762
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion (0.25 μg/kg/h for 24 h)
Study: 17137561
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 24 IU oxytocin
Study: 27453733
Drug: Insulin injections
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injections
Study: 12517044
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (containing antigens B/Yamanashi/166/98, A/New Caledonia/20/99 (H1N1), and A/Panama/2007/99 (H3N2))
Study: 9753207
Drug: Intravenous dolasetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dolasetron mesylate (200 mg)
Study: 9753207
Drug: Oral dolasetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dolasetron mesylate (200 mg)
Study: 9753207
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of hydrodolasetron and its metabolites
Study: 7826913
Drug: Mx 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mx 2% topical solution
Study: 3042005
Drug: Hydrocortisone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (3 grams intravenously in a 60 ml solution, repeated 6 times with 12-hour intervals)
Study: 31655378
Drug: SSRI+CBT (escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI+CBT (escitalopram 20 mg daily, 10 mg first week)
Study: 30955982
Drug: LBRV-PV (Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBRV-PV (Liquid Bovine-Human Reassortant Pentavalent Vaccine)
Study: 30955982
Drug: Rotasiil® (Lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotasiil® (Lyophilized Bovine-Human Rotavirus Reassortant Pentavalent Vaccine)
Study: 24192128
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment from community hospital interface programme nursing staff (Control group, n=10)
Study: 23611572
Drug: Pediatric formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric formulation of bosentan (64 mg as 2 pediatric tablets of 32 mg)
Study: 23611572
Drug: Adult formulation
Normalized name: Recombivax HB (Adult Formulation) 10mcg/ml Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult formulation of bosentan (62.5 mg as 1 adult tablet)
Study: 21561527
Drug: Acetaminophen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,000 mg) + Ibuprofen (400 mg)
Study: 21561527
Drug: Acetaminophen (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (325 mg) + Codeine (30 mg)
Study: 19136749
Drug: Amiodarone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (3 mg/kg)
Study: 11355042
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral micronized E2 daily for 16 months
Study: 11355042
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 delivered at a rate of 0.05 mg/day
Study: 11355042
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 delivered at a rate of 0.1 mg/day
Study: 11355042
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch for 9 months
Study: 3109581
Drug: Positive consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive consultation (with treatment)
Study: 3109581
Drug: Positive consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive consultation (without treatment)
Study: 3109581
Drug: Negative consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative consultation (with treatment)
Study: 3109581
Drug: Negative consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative consultation (without treatment)
Study: 2550696
Drug: Lisinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5 mg/day)
Study: 8393685
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg/day)
Study: 7234826
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg/day)
Study: 21831438
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg/HCT 12.5 mg
Study: 21831438
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg monotherapy
Study: 21831438
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg/HCT 12.5 mg
Study: 21831438
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg monotherapy
Study: 21831438
Drug: Candesartan-HCT combination
Normalized name: candesartan / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan-HCT combination therapy
Study: 16335887
Drug: Candesartan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan monotherapy
Study: 15295717
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg
Study: 19217077
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day to 150 mg/day)
Study: 16202731
Drug: HMR 3339
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 3339 50 mg
Study: 16202731
Drug: HMR 3339
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 3339 2.5 mg
Study: 17146377
Drug: HMR 3339
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMR 3339 10 mg
Study: 11314743
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous corticosteroid therapy (1 g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks)
Study: 11314743
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months)
Study: 2896810
Drug: Continuing chemotherapy
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing chemotherapy (Arm A)
Study: 2896810
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further chemotherapy until morphological relapse (Arm B)
Study: 2896810
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further chemotherapy until increase in myeloblast antigens (Arm C)
Study: 25321621
Drug: Remifemin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifemin (20 mg bid po)
Study: 25321621
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg qd po)
Study: 18271235
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (48 hours to 1 week after operation) with various acupoints (Neiguan, Qu‐chi, Waiguan, Hegu, Binao, Jianyu, Fengshi, Xuehai, Yinlingquan, Sanyinjiao, Taichong)
Study: 18271235
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of neurosurgical operation and drug treatment (Mannitol, Citioline Sodium, Cefeazidime, etc.)
Study: 15608034
Drug: Intracervical sodium
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical sodium nitroprusside gel (10 mg)
Study: 27406646
Drug: Aldosterone antagonists
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonists
Study: 12798839
Drug: Warfarin substitute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin substitute
Study: 7037036
Drug: Salbutamol nebulized
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulized with IPPB (5 mg)
Study: 27121262
Drug: Ixazomib 4
Normalized name: ixazomib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 4 mg (normal hepatic function)
Study: 27121262
Drug: Ixazomib 2.3
Normalized name: ixazomib 2.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 2.3 mg (moderate hepatic impairment)
Study: 27121262
Drug: Ixazomib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 1.5 mg (severe hepatic impairment)
Study: 27121262
Drug: Recommended starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recommended starting dose for ixazomib
Study: 17425550
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) via vacuum-assisted closure (VAC) device
Study: 21129474
Drug: Standard wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard wound therapy (SWT)
Study: 19880578
Drug: 4‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐mg nicotine lozenge
Study: 9459471
Drug: Cocaine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 0.4 mg/kg
Study: 9459471
Drug: Cocaine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 0.2 mg/kg
Study: 2145791
Drug: Procaterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol (10 micrograms/inhalation)
Study: 2145791
Drug: Albuterol (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (90 micrograms/inhalation)
Study: 30922873
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid 5 to 10 mg or 10 mg once daily for 12 months, followed by variable adjusted doses during the open-label extension.
Study: 19402182
Drug: Captopril LPH
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril LPH 25 mg
Study: 19402182
Drug: Captopril LPH
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril LPH 50 mg
Study: 19402182
Drug: Capoten 50
Normalized name: Capoten 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capoten 50 mg
Study: 15213582
Drug: Methylphenidate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate plus psychosocial treatment (academic remediation, organizational skills training, psychotherapy, parent training, counseling, social skills training)
Study: 15213583
Drug: Methylphenidate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate plus attention control treatment
Study: 9691878
Drug: 0.2% ropivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine, 8 ml/h for 24 hours
Study: 9691878
Drug: 0.2% bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% bupivacaine, 8 ml/h for 24 hours
Study: 8964876
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg E2 valerate
Study: 6426830
Drug: Naloxone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.2 mg/kg)
Study: 7307425
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg propranolol intravenously (group 1)